Literature DB >> 29809017

Impact of Payload Hydrophobicity on the Stability of Antibody-Drug Conjugates.

Jakob W Buecheler1,2, Matthias Winzer2, Jason Tonillo2, Christian Weber2, Henning Gieseler3.   

Abstract

In silico screening of toxin payloads typically employed in ADCs revealed a wide range of hydrophobicities and sizes as measured by log P and topological polar surface area (tPSA) values. These descriptors were used to identify three nontoxic surrogate payloads that encompass the range of hydrophobicity defined by the ADC toxin training set. The uniform drug to antibody ratio (DAR) ADCs were prepared for each surrogate payload by conjugation to the interchain cysteine residues of a model IgG1 subtype mAb. Linkage of these surrogate payloads to a common mAb with a matched DAR value allowed for preliminary analytical interrogation of the influence of payload hydrophobicity on global structure, self-association, and aggregation properties. The results of differential scanning fluorimetry and dynamic light scattering experiments clearly revealed a direct correlation between the destabilization of the native mAb structure and the increasing payload hydrophobicity. Also, self-association/aggregation propensity examined by self-interaction biolayer interferometry or size exclusion HPLC was consistent with increased conversion of the monomeric mAb to higher order aggregated species, with the degree of conversion directly proportional to the payload hydrophobicity. In summary, these findings prove that the payload-dependent structure destabilization and enhanced propensity to self-associate/aggregate driven by the increasing payload hydrophobicity contribute to reduced ADC stability and more complex behavior when assessing exposure and safety/efficacy relationships.

Entities:  

Keywords:  antibody−drug conjugates; conjugation; physicochemical properties; protein aggregation; stability; thermal analysis

Mesh:

Substances:

Year:  2018        PMID: 29809017     DOI: 10.1021/acs.molpharmaceut.8b00177

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  15 in total

1.  Site-Specific Bioconjugation and Multi-Bioorthogonal Labeling via Rapid Formation of a Boron-Nitrogen Heterocycle.

Authors:  Tak Ian Chio; Han Gu; Kamalika Mukherjee; L Nathan Tumey; Susan L Bane
Journal:  Bioconjug Chem       Date:  2019-05-03       Impact factor: 4.774

2.  Development of Cancer Immunotherapies.

Authors:  Diana C DeLucia; John K Lee
Journal:  Cancer Treat Res       Date:  2022

Review 3.  Antibody-drug conjugate as targeted therapeutics against hepatocellular carcinoma: preclinical studies and clinical relevance.

Authors:  A R Kumar; M Murali; B Nair; K Pavithran; A R Devan; G K Pradeep; L R Nath
Journal:  Clin Transl Oncol       Date:  2021-09-30       Impact factor: 3.405

Review 4.  New Technologies Bloom Together for Bettering Cancer Drug Conjugates.

Authors:  Yiming Jin; Shahab Edalatian Zakeri; Raman Bahal; Andrew J Wiemer
Journal:  Pharmacol Rev       Date:  2022-07       Impact factor: 18.923

Review 5.  Considerations for the Nonclinical Safety Evaluation of Antibody-Drug Conjugates.

Authors:  J Edward Fisher
Journal:  Antibodies (Basel)       Date:  2021-04-19

Review 6.  Antibody Conjugates-Recent Advances and Future Innovations.

Authors:  Donmienne Leung; Jacqueline M Wurst; Tao Liu; Ruben M Martinez; Amita Datta-Mannan; Yiqing Feng
Journal:  Antibodies (Basel)       Date:  2020-01-08

7.  Decorating sdAbs with Chelators: Effect of Conjugation on Biodistribution and Functionality.

Authors:  Henri Baudhuin; Janik Puttemans; Heleen Hanssens; Philippe Vanwolleghem; Sophie Hernot; Geert Raes; Catarina Xavier; Tony Lahoutte; Pieterjan Debie
Journal:  Pharmaceuticals (Basel)       Date:  2021-04-25

8.  Non-Genetic Generation of Antibody Conjugates Based on Chemoenzymatic Tyrosine Click Chemistry.

Authors:  Jorick J Bruins; Johannes A M Damen; Marloes A Wijdeven; Lianne P W M Lelieveldt; Floris L van Delft; Bauke Albada
Journal:  Bioconjug Chem       Date:  2021-09-14       Impact factor: 4.774

9.  Fcγ Receptor-Dependent Internalization and Off-Target Cytotoxicity of Antibody-Drug Conjugate Aggregates.

Authors:  Michihiko Aoyama; Minoru Tada; Hidetomo Yokoo; Yosuke Demizu; Akiko Ishii-Watabe
Journal:  Pharm Res       Date:  2021-12-27       Impact factor: 4.200

10.  Exatecan Antibody Drug Conjugates Based on a Hydrophilic Polysarcosine Drug-Linker Platform.

Authors:  Louise Conilh; Guy Fournet; Eric Fourmaux; Angélique Murcia; Eva-Laure Matera; Benoît Joseph; Charles Dumontet; Warren Viricel
Journal:  Pharmaceuticals (Basel)       Date:  2021-03-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.